Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research report issued on Sunday. The brokerage set a “sell” rating on the stock.

Oragenics Price Performance

Oragenics stock opened at $0.36 on Friday. Oragenics has a 1-year low of $0.25 and a 1-year high of $7.74. The business has a fifty day moving average price of $0.32 and a 200-day moving average price of $0.76. The stock has a market capitalization of $4.34 million, a price-to-earnings ratio of -0.05 and a beta of 0.43.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.